Rezultati pretrage - Michał Pochopień

The cost-effectiveness of pegcetacoplan in complement treatment-naive adults with paroxysmal nocturnal hemoglobinuria in the USA od Jesse Fishman, Koo Wilson, Aleksandra Drzewiecka, Michal Pochopien, David Dingli

Connect to this object online.

The impact of amortization of gene therapies funding on the results and conclusions of CEMs and BIMs od Hubert Polek, Justyna Janik, Ewelina Paterak, Monique Dabbous, Michał Pochopień, Mondher Toumi

Connect to this object online.

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies od Michal Pochopien, Annette Beiderbeck, Phil McEwan, Richard Zur, Mondher Toumi, Samuel Aballéa

Connect to this object online.

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models od Michał Pochopień, Ewelina Paterak, Emilie Clay, Justyna Janik, Samuel Aballea, Małgorzata Biernikiewicz, Mondher Toumi

Connect to this object online.

Gene Therapy Evidence Generation and Economic Analysis: Pragmatic Considerations to Facilitate Fit-for-Purpose Health Technology Assessment od Tingting Qiu, Michal Pochopien, Shuyao Liang, Gauri Saal, Ewelina Paterak, Justyna Janik, Mondher Toumi

Connect to this object online.

Cost-Effectiveness Analysis of Innovative Therapies for Patients with Non-Alcoholic Fatty Liver Disease od Michal Pochopien, Jakub Wladyslaw Dziedzic, Samuel Aballea, Emilie Clay, Iwona Zerda, Mondher Toumi, Borislav Borissov

Connect to this object online.